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Yielding Mammalian Cell Cultures Enabled Through
Oxygen Transfer Rate MeasurementsStephen Goldrick, Kenneth Lee, Christopher Spencer, William Holmes, Marcel Kuiper,
Richard Turner, and Suzanne S. Farid*Glucose control is vital to ensure consistent growth and protein production
in mammalian cell cultures. The typical fed-batch glucose control strategy
involving bolus glucose additions based on infrequent off-line daily samples
results in cells experiencing significant glucose concentration fluctuations
that can influence product quality and growth. This study proposes an on-
line method to control and manipulate glucose utilizing readily available
process measurements. The method generates a correlation between the
cumulative oxygen transfer rate and the cumulative glucose consumed. This
correlation generates an on-line prediction of glucose that has been
successfully incorporated into a control algorithm manipulating the glucose
feed-rate. This advanced process control (APC) strategy enables the glucose
concentration to be maintained at an adjustable set-point and has been
found to significantly reduce the deviation in glucose concentration in
comparison to conventional operation. This method has been validated to
produce various therapeutic proteins across cell lines with different glucose
consumption demands and is successfully demonstrated on micro (15mL),
laboratory (7 L), and pilot (50 L) scale systems. This novel APC strategy is
simple to implement and offers the potential to significantly enhance the
glucose control strategy for scales spanning micro-scale systems through to
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Mammalian cell cultures are the primary
source of therapeutic proteins in the
biopharmaceutical industry.[1] A platform
for commercial production of these pro-
teins involves a fed-batch protocol where
the initial media charge supports growth
and production while subsequent feed
additions prevent nutrient depletion and
sustain protein production.[2,3] Luan et al.[4]
initially demonstrated the beneﬁts of
conventional fed-batch operation of mam-
malian cells through enhanced cell viability
while maintaining a cell density equal to
2.1 106 cellsmL1 in addition to increas-
ing the monoclonal antibody (mAb) con-
centration four-fold to 0.140 g L1
compared to similar batch cell cultures.
Over the last three decades, signiﬁcant
advances in cell lines,[5] media optimiza-
tion,[6] bioreactor design,[7,8] and process
understanding[9,10] have enabled fed-batch
mammalian cultures to reach cell densities
greater than 100 106 cellsmL1 and mAb
titers in excess of 8 g L1.[11] The ability of a
fed-batch protocol to support high cell
densities and work across multiple scales(15mL to 20 000 L) while maintaining low operational
complexity demonstrates why the fed-batch protocol is the
standard operation for the majority of biopharmaceutical
facilities.
In fed-batch mammalian cell cultures, the primary carbon
source is glucose. Glucose is typically fed as a bolus addition
based on daily off-line concentrations of the nutrient. A
drawback of this control strategy is the resultant rapid change
to the cellular environment resulting in metabolic deregulation
of the glucose uptake rate.[12,13,14] Furthermore, excessive
glucose feeding has been shown to increase toxic by-products
such as lactate and ammonia.[15–18] whereas insufﬁcient feeding
can lead to nutrient depletion. More recently the glucose
concentration was shown to inﬂuence glycosylation and
antibody production.[19] The glucose concentration can be
maintained at a lower concentration by increasing the frequency
of the off-line samples and subsequent bolus additions, however
this strategy results in a higher contamination risk and annal Published by Wiley-VCH Verlag GmbH & Co. KGaA
www.advancedsciencenews.com www.biotechnology-journal.comincreased workload. Therefore, a non-invasive on-line glucose
prediction is preferred. With the evolution of the process
analytical technology (PAT) initiative[20] there have been
signiﬁcant advancements related to soft-sensor development
enabling on-line control of the key process parameters of
mammalian cell operation.[21,22] A wide range of spectroscopic
devices demonstrate the ability to monitor glucose on-line,
including near infrared,[23] mid-infra-red[24] and Raman spec-
troscopy.[25–27] However, the wide-spread application of spectro-
scopic PAT devices has been limited due to their high cost and
the challenges associated with conversion of spectroscopic data
into useful and reliable on-line predictions [28]. Alternative
methods to estimate on-line glucose involve evaluation of the
oxygen uptake rate through the dynamic method (OURdynamic)
and the development of a stoichiometric relationship between
glucose and oxygen consumption rates.[29–32] However, the
OURdynamic method results in signiﬁcant dissolved oxygen
(DO2) concentration ﬂuctuations ranging from 20 to 70% of
saturation throughout the cell culture process.[29,30] Further-
more, this method typically ignores adjustments to agitator
speed or shifts in gas-ﬂow rates by assuming a constant oxygen
mass transfer coefﬁcient (kLa). Off-gas analyzers have also been
demonstrated as an effective tool to monitor and control
mammalian cell cultures.[33–35] However these sensors can be
expensive and installation can be problematic on micro-scale
systems.
The methodology outlined here requires no adjustments to
normal operation and utilizes readily available process measure-
ments. Furthermore, the method automatically adjusts the
generated correlation to account for metabolic shifts throughout
the process and therefore can handle various nutrient uptake
rates present in different cell lines. The proposed on-line glucose
advanced process control (APC) strategy correlates the con-
sumption rate of glucose to the oxygen transfer rate (OTR)
enabling an on-line prediction of glucose throughout the cell
culture run. The on-line glucose APC strategy maintains the
glucose concentration closer to its target set-point with a
signiﬁcant reduction in glucose concentration ﬂuctuations and
was demonstrated across multiple scales. Comparable cell
culture proﬁles and product quality were also observed as
compared to conventional fed-batch bolus glucose control. The
ability of the on-line glucose APC strategy to visualize and
manipulate the glucose concentration in real-time is a step
toward enhanced process understanding enabling further
capabilities for process optimization. Furthermore, the recent
shift toward a “Quality by Design” approach emphasizing
product and process understanding through improved control
strategies and sound science is demonstrated by this
methodology.2. Experimental Section
2.1. Cell Line and Culture Propagation
Cell culture runs were performed using ﬁve different recombi-
nant Chinese hamster ovary (CHO) cell lines expressing high
levels of therapeutic proteins. The cell lines were cultured in
animal component-free chemically deﬁned CHO media. TheBiotechnol. J. 2018, 1700607 1700607 (2 of 10) © 2018 Thecells were maintained in shake ﬂasks at 37 C under 5% carbon
dioxide, shaken at a constant rpm and passaged 2–3 times per
week for propagation and scale-up for inoculation.2.2. Bioreactor Systems
Three different bioreactor systems were used for this study.
Micro-scale experiments were performed on the AmbrTM-15
system (TAP Biosystems, Greenville, DE) that was operated as
described in Ref. [36] with 24 single vessels split into two separate
culture stations where each vessel was operated with a 11–15mL
working volume. Laboratory-scale experiments were performed
in 7 L bioreactors (Applikon Biotechnology, Schiedam, The
Netherlands) with a working volume of approximately 5 L. Large-
scale experiments were performed at the 50 L bioreactor scale
(Applikon Biotechnology).2.3. Cell Culture Process
All cell culture runs had an initial seeding density of roughly
1 106 cellsmL1. Temperature was maintained at 35.5 C. The
dissolved oxygen set point was 50% of saturation and was
maintained through gassing with air ﬂow supplemented with
oxygen and manipulation of the agitation rate. The nutrient
feeding strategy consisted of six equally spaced additions of a
proprietary feed. The culture pH was controlled through the
addition of sodium carbonate and sparging CO2 gas with a pH
dead-band equal to 0.1. Antifoam was added as required. Daily
off-line samples were analyzed for viable cell concentration
(VCC) and viability using the Vi-Cell Automated cell viability
analyzer (Beckman Coulter, Brea, CA, USA). Glucose and lactate
were analyzed using the Bioproﬁle ﬂex (Nova Biomedical
Corporation, Waltham, MA, USA).2.4. Titer Analysis
Volumetric antibody titres in cell culture supernatants were
quantiﬁed by protein A afﬁnity chromatography using a protein
A ImmunoDetection sensor cartridge (Applied Biosystems,
Warrington, UK) coupled to an Agilent 1200 series HPLC
(Agilent, Berkshire, UK). Peak areas relative to a reference
standard calibration curve were used to calculate titres. These
samples were analyzed for titer on days 4–14 for each cell culture
run.2.5. Fed-Batch Bolus Glucose Control
The fed-batch bolus glucose control strategy involved measuring
the off-line glucose concentration (Gluc) every 24 h. If the
glucose concentration was below a pre-deﬁned minimum
(Glucmin), a bolus addition of glucose (VGluc) was added to raise
the concentration of glucose in the reactor to a target set-point
concentration (GlucS.P). Glucose concentrations above this
minimum value resulted in no bolus additions. The fed-batch
bolus glucose feeding script is summarized as:Authors. Biotechnology Journal Published by Wiley-VCH Verlag GmbH & Co. KGaA
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VGluc ¼ ðGlucS:P  GlucÞVCGluc
else VGluc ¼ 0
end
where V represents the volume of the culture and CGluc the
concentration of glucose in the feed solution.2.6. On-Line Glucose Advanced Process Control Strategy
Figure 1A outlines both the on-line and off-line process
measurements in addition to the bioreactor dimensions
required for implementation of the on-line glucose advanced
process control (APC) strategy. The on-line measurements
required by the control strategy for the calculation of the
cumulative oxygen transfer rate (OTR) are the agitator speed
(RPM), dissolved oxygen concentration (DO2), dissolved oxygen
concentration at maximum saturation (DO2) and inlet gas ﬂow
rate (Fgas). The maximum oxygen saturation concentration is
deﬁned by the partial pressure of the dissolved oxygen in the
inlet gas ﬂow. These measurements enable the calculation of
agitator power (Pag) and the superﬁcial gas velocity (Vs) using the
bioreactor dimensions deﬁned in Table 1A. The kLa coefﬁcients
were estimated for each bioreactor scale using the dynamic
gassing-out method outlined in Ref. [37] and are deﬁned in
Table 1A. The measurements required for the cumulative
glucose consumption rate (Gluccon) and the cumulative glucose
added (GlucAdd) are the off-line concentration of glucose (Gluc)
and the volume of glucose added (VGluc).
The on-line glucose APC algorithm implemented for the 7
and 50 L bioreactor systems is shown in Figure 1B. This control
strategy involves the execution of two scripts running at two
different frequencies. The outer script runs every n time-points
(every 10 s in this work) and continuously calculates the
cumulative oxygen transfer rate, OTR(n), and the cumulative
glucose added, GlucAdd(n). The inner script runs every time a
new off-line measurement of glucose is added, deﬁned here as
every k time-point (approximately every 24 h). The inner script
calculates the cumulative glucose consumed, GlucCon(k), based
on the current and previous glucose concentration and the
known amount of glucose added to the bioreactor during this
relevant time period. Similarly, theOTR(k) is calculated for each
of these k time-points. A linear relationship between the GlucCon
andOTR is deﬁned by the equation: GlucCon¼mOTRþb. The
slope of the line, m, and the intercept, b, are recalculated every k
time-point utilising the three most recent values of GlucCon and
OTR. The generated correlation enables an on-line prediction of
the cumulative glucose consumed utilizing the OTR(n) and the
most recent m and b values. To maintain the glucose
concentration at its set-point, GlucS.P, the algorithm switches
on the glucose feed, FGluc, if the predicted cumulative glucose
consumed is higher than the total glucose added to the vessel
after considering the initial glucose concentration. For the
AmbrTM-15 bioreactor system the script was slightly adjusted to
account for the liquid handling system with the outer scriptBiotechnol. J. 2018, 1700607 1700607 (3 of 10) © 2018 Therunning every 30min to enable time for glucose to be added to
each of the 24 vessels after its execution. By deﬁning GlucS.P as
an external variable in the control algorithm, the set-point can be
manipulated in real-time throughout the cell culture run.3. Results
3.1. Correlation Development Between Cumulative Glucose
Consumed and Cumulative Oxygen Transfer Rate
The utilization of the oxygen uptake rate (OUR) to predict
glucose consumption in mammalian cell culture processes is
well established.[29,30,33] However, the dynamic method for OUR
calculation is cumbersome and requires signiﬁcant and repeated
dissolved oxygen deviations throughout the cell culture.
Utilization of the OTR to act as a metabolic indicator for
mammalian cell cultures is far less publicized. Moreover, the
OUR and OTR are essentially equal during steady-state
conditions through analysis of the oxygen mass balance within









¼ 0;OTR ¼ OUR ð1Þ
To demonstrate the ability of the OTR to act as a suitable
monitoring tool in mammalian cell cultivations, the cumulative
sum of the OTR was compared against the cumulative sum of
the glucose consumed for three highly diverse cell lines (cell
lines A, B, and C). The strength of this linear relationship is
shown in Figure 2A. The on-line OTR was calculated
continuously using the readily available process measurements
deﬁned in Figure 1. Taking the cumulative sum of the calculated
OTR values ﬁlters out some of the rapid ﬂuctuations due to the
random deviations in DO2 and gas ﬂow rates and therefore
strengthens the correlation with the cumulative glucose
consumed.
Figure 2 A highlights a moderately sigmoidal pattern for each
of the cell lines investigated here, particularly for cell lines B and
C. These slight nonlinearities represent shifts in the stoichio-
metric ratio of the glucose to oxygen consumption rates
throughout the cell culture run. This is particularly evident
during the early and late stages of the run for each of these high-
yielding cell lines. The observed changes to this ratio could
represent differences in uptake rates as the cells shift from the
exponential phase to stationary phase. Furthermore, the
metabolic shift from lactate production to lactate consumption
could also contribute to this slightly sigmoidal pattern as was
demonstrated by Ref. [38] in a mammalian cell culture run. The
relationship between the OTR compared to the cumulative
glucose consumed (Gluccon) was quantiﬁed using the correlation
coefﬁcient (R2) displayed in Figure 2B. The strong linear
relationship between these OTR and Gluccon demonstrates the
ability of this easily calculated and high frequency measurement
to be used as a soft-senor for on-line prediction of glucose.Authors. Biotechnology Journal Published by Wiley-VCH Verlag GmbH & Co. KGaA
Figure 1. A) Schematic outlining bioreactor dimensions and on- and off-line variables required to implement the on-line glucose APC strategy. B)
Outline of on-line glucose APC algorithm manipulating the glucose feed rate based on predicted glucose consumed (GlucCon) derived from the
cumulative oxygen transfer rate (OTR).
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Batch Bolus Glucose Control
The on-line glucose APC algorithm developed in this work has
been compared to the standard fed-batch bolus glucose feeding
strategy for a wide range of cell lines and scales. Figure 3
summarizes the performance of the algorithm for three separate
cell lines carried out at the 7 L scale. The typical controller action
of the fed-batch bolus feeding control strategy for cell line A isBiotechnol. J. 2018, 1700607 1700607 (4 of 10) © 2018 Theshown in Figure 3A. The fed-batch bolus feeding strategy is
described in section 2.5 and involves measuring the glucose
concentration approximately every 24 h. The glucose trigger rate
for the bolus addition was above 5 g L1 (Glucmin) resulting in no
glucose additions during the batch phase for cell culture run 1, 3,
and 5 as demonstrated in Figure 3C, E, and G. To ensure glucose
limitation does not occur, the bolus addition is calculated to raise
the glucose concentration to a target of 8 g L1 (GlucS.P). The
simple and accurate nature of this method is demonstrated forAuthors. Biotechnology Journal Published by Wiley-VCH Verlag GmbH & Co. KGaA
Table 1. (A) Summary of bioreactor dimensions and oxygen mass transfer coefficients required for implementation of the on-line glucose APC
strategy. (B) Comparison of the mean and standard deviation of glucose concentration controlled using a fed-batch feeding strategy (indicated as
“Bolus”) and on-line glucose advanced process control (APC) strategy (indicated as “APC”).
A)
Bioreactor parameter Micro (15mL) Lab (7 L) Large (50 L)
Bioreactor radius: r (m) 0.0115 0.06 0.175
Impeller dimeter: Dimp(m) 0.0114 0.055 0.12
Power number: Po () 2.1 1.7 2.2
kLa coefficients: () 1.74, 0.30, 0.16 73.5, 0.43, 0.24 81, 0.35, 0.6
B)
Cell Culture ref Cell line Scale Glucose control strategy Mean glucose conc (g L1) Standard deviation (g L1)
Cell culture run1 Cell line A 7-L Bolus 4.70 1.85
Cell culture run1 Cell line A 7-L APC 2.47 0.57
Cell culture run 3 Cell line B 7-L Bolus 5.19 1.59
Cell culture run 4 Cell line B 7-L APC 2.62 1.01
Cell culture run 5 Cell line C 7-L Bolus 5.71 1.53
Cell culture run 6 Cell line C 7-L APC 2.31 0.88
Cell culture run 7–9 Cell line D 7-L Bolus 4.01 1.71
Cell culture run 10–12 Cell line D 7-L APC 2.35 1.31
Cell culture run 13–18 Cell line E 7-L Bolus 4.80 1.41
Cell culture run 19–20 Cell line E 7-L APC 3.39 1.42
Cell culture run 21 Cell line A 50-L Bolus 5.56 2.76
Cell culture run 22 Cell line A 50-L APC 2.91 1.13
Cell culture run 23–34 Cell line A 15-mL Bolus 5.67 2.32
Cell culture run 35–46 Cell line A 15-mL APC 3.76 1.73
www.advancedsciencenews.com www.biotechnology-journal.comeach cell line in Figure 3C, E, and Gwhere the target glucose set-
point is reached after each bolus addition. The on-line glucose
concentration shown in Figure 3 was estimated by a mass
balance incorporating the cumulative glucose consumed using
the off-line glucose concentration measurements and the known
quantity of glucose added to the reactor.
Figure 3B represents the typical controller action for the
glucose ﬂow rate implementing the on-line glucose APC strategy
and was demonstrated here for cell culture run 2. The algorithm
implements an “if-statement” that continuously switches the
glucose pump on or off. The pump is switched on if the predicted
cumulative on-line glucose concentration generated through the
OTR correlation is higher than the cumulative glucose added to
the vessel after taking the initial glucose concentration and the
set-point (GlucS.P) into consideration. The on-line glucose APC
strategy implemented for three separate cell lines is shown for
cell culture runs 2, 4, and 6 in Figure 3D, F, and H. The average
glucose concentration for the bolus controlled cell culture runs 1,
3, and 5 is approximately 5.2 g L1 with a standard deviation
equal to 1.66 g L1. Enhanced control was observed for the cell
culture runs 2, 4, and 6 implementing the on-line glucose APC
strategy where the average glucose concentration was equal to
2.52 g L1 with a standard deviation equal to 0.71 g L1. The
target glucose set concentration for all cell culture runs was equal
to 2 g L1. Furthermore, the on-line glucose APC strategy
signiﬁcantly reduced the high ﬂuctuation in the glucose
concentration observed after each daily bolus addition.Biotechnol. J. 2018, 1700607 1700607 (5 of 10) © 2018 The3.3. Comparison of Growth Profiles for On-Line Glucose
APC Strategy to Fed-Batch Bolus Glucose Control
Figure 4 compares the off-line variables of the conventional fed-
batch bolus glucose control and the on-line glucose APC strategy
controlled runs during the cultivation of cell lines A, B and C (cell
culture runs 1–6). Each of the cell lines had highly varied viable
cell densities and different monoclonal antibody production
rates resulting in different glucose consumption rates. These
highly diverse cell lines therefore represent a signiﬁcant control
challenge requiring an adaptive glucose feeding strategy. The
ability of the on-line glucose APC strategy to dynamically adjust
the glucose uptake demands of these diverse cell lines is
demonstrated in Figure 3 and highlights the robustness of the
proposed algorithm. Furthermore, the on-line glucose APC
strategy demonstrates excellent comparability to the fed-batch
cultures for growth, viability, lactate, and titer as shown in
Figure 4A–D, respectively. The very high peak cell density
reached (4.5 107 cellsmL1) for cell line A during the
production phase represents a signiﬁcant control challenge
based on the high glucose consumption demand.
Figure 3C highlights the rapid consumption rate of glucose
where the glucose concentration is almost depleted between
each sample particularly during the production phase of this cell
line. Typically to alleviate this issue, biopharmaceutical compa-
nies manually raise the target set-point for the bolus additions
for the stationary phase to ensure glucose limitation does notAuthors. Biotechnology Journal Published by Wiley-VCH Verlag GmbH & Co. KGaA
Figure 2. A) Correlation of cumulative glucose consumed (GlucCon) with
the cumulative oxygen transfer rate (OTR) for three different cell lines. Cell
line A is represented by the blue dashed dot line, cell line B by the red solid
line and cell line C by the green dotted line. Color images are available for
the on-line version. B) Table highlighting the correlation coefficient (R2)
for OTR compared to the cumulative glucose consumed for cell culture
runs 1, 3, and 5.
www.advancedsciencenews.com www.biotechnology-journal.comoccur as demonstrated in Ref. [19]. The adaptive nature of the on-
line glucose APC strategy ensures that glucose levels are
maintained near their set-point and require no manual adjust-
ments throughout the cell culture run. Furthermore, this control
strategy demonstrates consistent therapeutic protein production
for highly varied cell lines including high yielding cell culture
runs enabling titres in excess of 6 g L1 as demonstrated in
Figure 4D.3.4. Consideration of Lactate Metabolism
The on-line glucose APC strategy assumes that the OTR
requirements of the cell culture indicate the required glucose
demand for cell proliferation and protein production. The energy
required by these cellular activities is produced by the TCA cycle
driven by the metabolism of glucose to pyruvate by glycolysis.
The proposed APC strategy only considers the aerobic
metabolism of glucose to energy and does not take into account
the anaerobic conversion of glucose to lactate. To investigate
whether the inclusion of lactate in the proposed APC strategy
would improve the control of glucose, the algorithm was
adjusted to take into account the off-linemeasurements of lactate
that were recorded every 24 h similar to the off-line glucose
measurements. The modiﬁed algorithm is similar to the APC
strategy outlined in Figure 1 however the cumulative glucose
consumed is deﬁned as:Biotechnol. J. 2018, 1700607 1700607 (6 of 10) © 2018 TheGlucConðkÞ ¼ Glucð0Þ GlucAddðnÞ  GlucðkÞ  LactðkÞ ð2Þ
where (k) and (n) refer to off-line samples (every 24 h) and on-line
samples (every 10 s), respectively. The off-line lactate concentra-
tion is represented as Lact(k) and the cumulative glucose
consumed is deﬁned as GlucAdd. The inclusion of lactate in the
control algorithm resulted in tighter control of glucose by
reducing the standard deviation of the glucose concentration
compared to the on-line glucose APC algorithm without lactate.
Zhou and Hu[29] also included the lactate in their stoichiometric
relationship with the OUR measurements and demonstrated
high correlations between the cumulative glucose consumed and
the cumulative OURdynamic. Although the inclusion of lactate
marginally improved the APC strategy in this work, the
additional off-line measurement further complicates the algo-
rithm and is not necessary based on the signiﬁcantly enhanced
glucose control demonstrated utilising solely the off-line glucose
measurement. Furthermore, the inclusion of the lactate in the
control algorithm requires the additional validation of the off-
line lactate measurement in comparison to the standard
operation implementing a fed-batch bolus glucose feeding
regime.[39]3.5. Validation of On-Line Glucose APC Strategy Across
Multiple Scales and Multiple Cell Lines
To demonstrate the robustness and adaptability of the proposed
on-line glucose APC strategy, the performance of the algorithm
was compared against conventional fed-batch bolus glucose
control for ﬁve different cell lines operated at three scales. The
three scales chosen to validate the APC algorithm were a micro-
scale using the advanced micro-bioreactor system (AmbrTM-15)
with a volume of 15mL, a standard laboratory scale with a 7 L
volume, and a 50L pilot scale system. To implement the APC
strategy on the different scales, the bioreactor dimensions and the
kLa coefﬁcients had to be adjusted for each system as deﬁned in
Table 1A. To challenge the algorithmat pilot scale, Cell lineA (high
glucose consumption demand) was chosen to validate themethod
at the 50L scale. A comparison of the performance of the on-line
glucose APC strategy and fed-batch bolus glucose control is
summarized in Table 1B. The algorithm demonstrated a
signiﬁcant reduction in the mean glucose concentration and
glucose deviations across all cell culture runs for all scales
investigated. Furthermore, across all scales, the bioreactor growth
proﬁles were highly comparable to those using bolus feeding.3.6. Product Quality Comparisons Between Fed-Batch Bolus
Glucose Control and On-Line Glucose APC
Glycosylation is a critical protein quality attribute that can
modulate the efﬁcacy of a commercial therapeutic.[40] Main-
taining consistent glycosylation proﬁles between cell culture
runs is therefore necessary to ensure constant therapeutic
efﬁcacy for commercial products. To ensure the glycosylation
patterns of the proteins produced were comparable for each
glucose control method, the N-linked glycosylation patterns ofAuthors. Biotechnology Journal Published by Wiley-VCH Verlag GmbH & Co. KGaA
Figure 3. Feed additions of glucose (FGluc) for (A) the bolus fed-batch strategy for cell culture run 1 and (B) the on-line glucose APC strategy for cell
culture run 2. Glucose concentrations for cell culture runs 1 (C), 3 (E), and 5 (G) controlled by fed-batch control and for cell culture runs 2 (D), 4 (F), and
6 (H) controlled by the online glucose APC strategy. The off-line concentrations are represented by the red squares and the calculated glucose
concentration is represented by the solid blue lines based on a subsequent mass balance.
www.advancedsciencenews.com www.biotechnology-journal.com
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Figure 4. Comparison of kinetic profiles of three different mAb products (cell culture runs 1–6) controlled through bolus fed-batch glucose additions
(solid lines) and the on-line glucose APC strategy (dashed lines) for the off-line variables (A) viable cell density, (B) viability, (C) lactate and (D) titre. The
cell lines A, B, and C are represented by the blue, red, and pink lines, respectively.
www.advancedsciencenews.com www.biotechnology-journal.comcell line D were examined. These were measured on days 8, 10,
12, and 14 for cell culture runs that were controlled through fed-
batch and APC feeding strategies. Both glucose control methods
were found to adequately maintain consistent glycosylation
patterns throughout the cell culture run as shown in S1
(supporting information) A, B, C, and D. Although the average
glucose concentration in the fed-batch bolus controlled runs is
almost twice as high as the APC strategy, no signiﬁcant changes
to the glycosylation proﬁles were observed for the particular cell
line investigated. However, these cell lines had been screened
using a fed-batch glucose protocol and selected speciﬁcally for
robustness and product quality. Further process yield improve-
ments could be potentially observed through incorporation of
this on-line glucose APC strategy into the cell line selection
protocol. Gagnon et al.[18] reported similar ﬁndings and found no
difference in glycosylation patterns during the comparison of a
conventional fed-batch process to an advanced glucose con-
trolled process. They suggested the consistent glycosylation
patterns were due to the ability of mammalian cells to regulate
their intercellular levels of glycosylation-related precursorBiotechnol. J. 2018, 1700607 1700607 (8 of 10) © 2018 Themolecules at transient levels of glucose. The application of this
methodology has the potential to improve product quality in cell
lines that are less robust or susceptible to large glucose
ﬂuctuations. For example, there have been reports where
changes to the glucose concentration and the feeding strategy
were shown to inﬂuence the glycan concentrations for multiple
cell lines.[19]4. Discussion
4.1. Strength of Correlation Between OTR and Glucose
Consumed
The application of the OTR to be utilized as a soft-sensor for on-
line glucose concentration is demonstrated by the highly linear
relationship between the cumulative values of the OTR and
glucose consumed for a wide range of cell lines shown in
Figure 2A. The strength of this linear relationship is
fundamental to the APC control strategy outlined in Figure 1Authors. Biotechnology Journal Published by Wiley-VCH Verlag GmbH & Co. KGaA
www.advancedsciencenews.com www.biotechnology-journal.comand enables real-time predictions of the glucose concentration
during the manufacture of various therapeutic proteins. Similar
linear relationships have been reported between the OUR and
glucose consumed for mammalian cell cultures.[28,29,41] How-
ever, the implementation of theOTR as an on-line predictive tool
offers signiﬁcant advantages in comparison to previous work
utilizing the dynamically calculated OUR for advanced control
applications.[28,29,32,42] To calculate the OUR in these previously
described studies signiﬁcant process deviations involving
dissolved oxygen shifts between 30 and 60% of saturation and
off-line data analysis are required. These complications in
addition to the potential mixing heterogeneities caused by the
dissolved oxygen ﬂuctuations limit the wide-spread application
of this method. Therefore, the on-line glucose APC strategy
proposed here involving the OTR is highly advantageous as it
requires no process deviations or set-point changes. Further-
more, the method acts completely unsupervized and only
requires operator input to add in the off-line glucose
concentration with all other process measurements automati-
cally acquired enabling the on-line predictions and control
actions to be implemented autonomously.4.2. Implementation of On-Line Glucose APC Strategy
The on-line glucose APC strategy outlined in this work is highly
robust and was successfully applied to three different scales,
15mL, 7 L, and 50 L and multiple cell lines as demonstrated in
Table 1B. The algorithm manipulated the glucose feed pump
based on a simple “if-statement” that continuously switched the
feed pump on and off depending on the predicted on-line
glucose concentration. The feed pump rate set-point was
10mLh1 and the execution time of the algorithm was every
10 s for the 7 L bioreactors used in this work as shown in
Figure 3B. The feed pump rate and execution time of the
algorithm were carefully chosen to ensure the glucose
concentration was adequately maintained throughout the
culture run. Furthermore, the glucose concentration set-point
of 2 g L1 was chosen to take in account any potential
inaccuracies in the off-line glucose concentrationmeasurements
and thus ensure that glucose limitation did not occur. These
parameters were found to be suitable for the varied glucose
consumption rates of the cell lines investigated here. The
glucose consumption rates ranged from cell line B with a peak
glucose consumption of 0.2 g of glucose per million cells to cell
line A with a glucose consumption rate of 0.5 g of glucose per
million cells. The high glucose requirements of these cell lines
posed a signiﬁcant control challenge for on-line glucose APC
strategy and demonstrated the robustness of the proposed
strategy. The control algorithm is highly adaptive and calculates
the stoichiometric ratio of glucose to oxygen requirement after
each off-line measurement of glucose is recorded. The calculated
correlation utilizes the three most recent values of the
cumulative glucose consumed and corresponding cumulative
OTR measurements thus minimizing any potential model-
mismatch as a result of inaccuracies in the off-line measurement
of glucose or process deviations inﬂuencing theOTR calculation.
The modiﬁcations necessary to implement the algorithm on
multiple scales are the bioreactor dimensions and the kLaBiotechnol. J. 2018, 1700607 1700607 (9 of 10) © 2018 Thecoefﬁcients thatwere easily calculated for the three different vessel
set-ups used in this work. To ensure that cellular oxygen demand
couldbemet acrossall scales a similarpowerperunit volume (P/V)
was used. This strategy enables the method to be implemented
across differentbioreactor scales in addition to awide variety of cell
lines with both high and low glucose demands.5. Conclusions
Current on-line methods to control glucose require expensive
process analytical technology (PAT) devices that have proven to
be difﬁcult to validate and are not commonly incorporated in
industrial biopharmaceutical facilities. One of the key require-
ments in the development of the on-line glucose APC strategy
for this study was to ensure that no additional sensors, off-line
analyzes, or signiﬁcant changes to standard operating proce-
dures (SOPs) were needed to enable its wide-spread application.
This simple to implement control strategy generates a
correlation between the cumulative oxygen transfer rate and
the cumulative glucose consumed enabling enhanced glucose
control. In comparison to conventional fed-batch bolus glucose
control, the on-line glucose APC strategy demonstrated similar
growth characteristics and product quality characteristics. Thus
the strategy is highly applicable and is suitable for integration
into biopharmaceutical facilities currently utilizing conventional
fed-batch control. The algorithm allows for real time visualiza-
tion of glucose concentration, enabling enhanced understanding
of the metabolic uptake rates of this critical process component.
This presents opportunities for more advanced fault detection
capabilities through real time analysis of glucose uptake rates
and opportunities to adjust glucose concentrations on-line to
maximize protein production and minimize inhibitory concen-
trations. The proposed method is highly robust and ﬂexible and
was veriﬁed at multiple scales and across multiple cell lines with
signiﬁcantly varied glucose uptake rates.Nomenclature
α, a, b, oxygenmass transfer coefﬁcients ();CGluc, concentration of
glucose in feed solution (g L1); DO2, dissolved oxygen (mgL
1);
DO2, dissolved oxygen at maximum saturation (mgL
1); Dimp,
impeller diameter (m);Fgluc, glucose feed ﬂowrate (Lh
1);Fgas, inlet
gas ﬂowrate (s h1); Gluc, off-line glucose concentration (g L1);
GlucS.P, off-line glucose concentration set-point (g L
1); kLa, oxygen
mass transfer rate (s1); k, off-line measurement time-point; Lact,
off-line lactate concentration (g L1); n, on-line measurement time-
point; OTR, oxygen transfer rate (mgLh1); Pag, agitator power
(kW); Po, unaerated power number (); r, bioreactor radius (m);
RPM, agitator rate (rmp); V, bioreactor volume (L); Vgluc, volume of
glucose added (L); VCD, viable cell density (cells 106 mL1); Vs,
superﬁcial gas velocity (ms1); ρ, density (kgL1).Acknowledgements
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